Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-MUC16/CD28 bispecific antibody REGN5668

A bispecific monoclonal antibody against both the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential antineoplastic and immunostimulating activities. Upon administration, anti-MUC16/CD28 bispecific antibody REGN5668 binds to both CD28 on T cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed by several epithelial cancers, including ovarian cancer.
Synonym:anti-MUC16 x anti-CD28 bispecific antibody REGN5668
MUC16xCD28 bispecific antibody REGN5668
Code name:REGN 5668
REGN-5668
REGN5668
Search NCI's Drug Dictionary